Compare BXBL & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXBL | CERT |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2023 | 2020 |
| Metric | BXBL | CERT |
|---|---|---|
| Price | $1.73 | $11.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $12.68 |
| AVG Volume (30 Days) | 135.1K | ★ 2.6M |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $1.76 | $4.45 |
| 52 Week High | $5.42 | $12.61 |
| Indicator | BXBL | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 22.17 | 62.32 |
| Support Level | N/A | $6.26 |
| Resistance Level | $4.60 | $11.73 |
| Average True Range (ATR) | 0.26 | 0.65 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 1.71 | 57.47 |
BOXABL Inc is engaged in building construction using modern manufacturing processes to create residential and commercial buildings that can be completed in less time and at lower cost than traditional construction. The Company has developed a building system using manufacturing processes and existing technologies and processes developed by the automotive industry. Its products include the Casita and other building solutions using patented folding and shipping technology to transport buildings on existing roadways across large geographic areas.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.